All articles tagged with #weight loss drugs
A new study presented at the European Academy of Dermatology and Venereology Congress found that people taking GLP-1 medications for obesity or diabetes are significantly more likely to experience nail detachment and hair loss than non-users. While the association is strong, experts caution that rapid weight loss and nutritional deficiencies may be the primary drivers rather than the drugs themselves.
Two new studies presented at the 2026 European Academy of Dermatology and Venereology Congress in Vienna found that individuals taking GLP-1 receptor agonists for obesity or diabetes experience significantly higher rates of nail detachment and hair loss compared to non-users. While the association is strong, experts caution that rapid weight loss and nutrient deficiencies may be the primary drivers rather than the drugs themselves.
A new study published in Clinical Nutrition identifies 15 cases of Wernicke encephalopathy, a rare and potentially fatal brain disorder caused by severe vitamin B1 deficiency, among users of GLP-1 weight-loss medications. The condition is linked to the drugs' side effects, such as nausea and appetite suppression, which can lead to malnutrition. While the study cannot prove causation, experts warn that patients experiencing persistent gastrointestinal symptoms or rapid weight loss should monitor their nutritional intake and hydration closely.
A new study ties two widely used GLP-1 weight-loss drugs, semaglutide (Ozempic/Wegovy/Rybelsus) and tirzepatide (Mounjaro/Zepbound), to a rare, potentially deadly brain disorder called Wernicke encephalopathy caused by vitamin B1 deficiency. In a review of about 196,000 cases, 15 WE instances were found, more common among GLP-1 users than with other drugs, often involving GI-related malnutrition. WE’s hallmark triad is inconsistently present (only 10–16% show it), making diagnosis tricky; however, early thiamine treatment can halt progression, while untreated WE can cause permanent brain damage or death. Clinicians are urged to monitor GLP-1 patients—especially those on semaglutide or tirzepatide with GI symptoms—for WE. The piece also notes that more than 10% of American adults are on GLP-1s for weight loss.
GLP-1 weight-loss drugs can curb appetite by prolonging GLP-1 activity, but they don’t erase hunger and come with GI side effects during dose increases. They may reduce overall intake and hydration needs, but poor diet can lead to nutrient deficiencies, and weight often returns after stopping treatment. There’s also potential lean-mass loss, so protein intake and resistance training are important. Effects vary by person, they are not a magic bullet or cosmetic shortcut, and research into long‑term benefits beyond weight loss is ongoing.
An observational study of 27,741 South Korean adults found that prescription weight‑loss medication users had higher rates of depression, mental-health counseling, suicidal thoughts and behaviors than non-users, with stronger associations among those who gained weight. The study cannot prove that the medications cause these mood changes, and older anti‑obesity drugs were analyzed. Experts call for baseline mental‑health screening and ongoing monitoring, and more research to separate drug effects from obesity‑related factors.
A study finds that GLP-1 medications used for weight loss may worsen or accelerate hair loss in some men, with cases of shedding lasting beyond a temporary phase. While anecdotes about Ozempic and similar drugs exist, the effect does not affect everyone, and more research is needed to understand who is affected and why.
GLP-1 medications used for weight loss can reduce persistent 'food noise'—thoughts about eating and body image—but experts warn that silencing these cues can mask hunger signals and nutritional needs, especially for people with or recovering from eating disorders. While some studies link GLP-1 use to fewer intrusive food thoughts, more research is needed, and clinicians stress monitoring weight, labs, intake, mood, and menstrual health while tailoring treatment to individual needs.
BBC InDepth argues that missing school during and after the Covid-19 era is a key, overlooked factor driving UK childhood obesity. About 6,000 severely obese children have been treated across 39 NHS CEW clinics, but the network reaches only around 5% of eligible youngsters. Persistent absence has risen from 10% to 18%, and experts say returning children to school improves diet, physical activity, and access to healthcare. While weight‑loss drugs are discussed, they aren’t a standalone fix; the broader solution involves healthcare support in schools, better monitoring, and boosting attendance to curb a £12bn NHS obesity-related cost.
A new observational study suggests that microdosing Wegovy (semaglutide) and Zepbound (tirzepatide) can lead to some weight loss, but far less than full-dose regimens and with different side effects; causation isn’t established. Over a year, low-dose tirzepatide users lost about 5.5% of body weight and low-dose semaglutide users about 2.2%, versus 20.2% and 13.7% in higher-dose trials. Side effects varied by drug and dose, with kidney-related issues and GI symptoms more common for tirzepatide, and ear inflammation, sweating, and ankle swelling more common for semaglutide. The study is observational and relies on electronic health records and AI-curated notes, so it cannot prove benefits or harms. Medical guidance emphasizes that weight loss at low doses is limited and decisions should be made with a healthcare provider; drugmakers continue to recommend gradual dose escalation to maintenance doses.
Weight-loss drugs such as GLP-1s have become ubiquitous, but the social judgment is flipping: people are shamed whether they take the meds or opt not to, with personal stories of pressure, rising medicalized weight talk, and experts urging not to replace old obesity stigma with a new form of coercion.
A Rutgers study suggests GLP-1 medications such as Ozempic and Wegovy may dampen impulsivity and alcohol use by affecting brain reward/self-control pathways, a possible factor in the U.S. decline in violent crime, though experts caution that correlation is not causation and long‑term effects remain uncertain.
Trump’s plan to negotiate discounted GLP-1 weight‑loss drugs for Medicaid has stalled: only Indiana has signed on, while 29 states will not participate due to tight budgets. Twelve states still cover GLP-1s, but five of those recently ended coverage (California, Massachusetts, New Hampshire, Pennsylvania and South Carolina), with Rhode Island set to end in October. As other states weigh participation, many cite cost concerns and the risk to budget sustainability, meaning access to these drugs for low-income Americans on Medicaid is shrinking even as some argue these medications could reduce long-term health costs.
BBC follows comedian Steffen Peddie’s personal use of weight-loss injections (Wegovy) to shed over 8 stone and examines why men discuss such treatments less openly than women. With about 1.6 million adults in England, Wales and Scotland estimated to have used weight-loss drugs in 2024–25 (often bought privately), the piece shares men’s experiences, the stigma and privacy surrounding use, reported side effects, and medical calls for open discussion and routine monitoring to ensure safe, effective use.
CNN reports that about half of parents taking GLP-1 weight-loss medications are already discussing the treatment with their children. Experts warn that secrecy or overly restrictive dieting talk can harm kids’ body image and risk eating disorders, so the piece advocates neutral, health-focused conversations, modeling balanced eating, and keeping health separate from weight. It also underscores kids’ ongoing caloric needs, offers practical tips for shared meals and responding to compliments on weight loss, and points to resources for eating-disorder support.